An open-label Phase III study of AZD0901 as monotherapy compared to standard therapy at the discretion of the investigator in adult participants with advanced/metastatic gastric cancer or gastroesophageal junction cancer expressing Claudin 18.2.
Descrizione riassuntiva dello studio
This study will investigate an investigational substance AZD0901 in advanced or metastatic gastric cancer, gastroesophageal junction cancer, or esophageal cancer. AZD0901 is a type of medication known as an antibody-drug conjugate (ADC). ADCs are a type of targeted therapy that delivers cancer drugs directly to cancer cells. AZD0901 recognizes cancer cells by a specific protein called Claudin 18.2. This is one of the proteins that is commonly found on the surface of gastric cancer cells. To be eligible for this study, this protein must be present in sufficient amounts on the cancer cells (expressed). This will be verified prior to inclusion in the study. This study aims to determine how effective (for example, by reducing the growth or spread of cancer) and safe AZD0901 is compared to a standard therapy. The standard therapy will be selected by the investigator based on the disease status (from a selection of Ramucirumab + Paclitaxel, Paclitaxel, Docetaxel, Irinotecan, TAS-102, or Apatinib).
(BASEC)
Intervento studiato
Participants will be randomly assigned to one of the following treatment groups:
A) AZD0901 2.2 mg/kg administered intravenously every 3 weeks.
B) AZD0901 1.8 mg/kg administered intravenously every 3 weeks.
C) Standard therapy selected by the investigator (visits expected every 3-4 weeks).
The optimal dose of AZD0901 (2.2 mg/kg or 1.8 mg/kg) is currently being determined in preliminary studies. Once this is established, either Arm A or Arm B will be closed early and the inclusion in the study will then continue 1:1 in two groups (AZD0901 or standard therapy).
Treatments will continue until disease progression occurs. They may also continue if there is clinical benefit.
(BASEC)
Malattie studiate
Advanced or metastatic Claudin 18.2-expressing gastric cancer (gastric adenocarcinoma), gastroesophageal junction cancer, or esophageal cancer.
(BASEC)
- Male and female patients (≥18 years) with a histologically confirmed inoperable, locally advanced, or metastatic gastric adenocarcinoma, gastroesophageal junction cancer, or esophageal cancer expressing the protein Claudin 18.2, but not HER2 (=exclusion). - ECOG performance status 0-1 - Adequate organ and bone marrow function - Non-HER2-positive adenocarcinoma with demonstrated CLDN18.2 expression (status confirmed by central laboratory) - Progression on or after at least one prior treatment with a fluoropyrimidine and a platinum agent. (BASEC)
Criteri di esclusione
- Significant or unstable gastric bleeding and/or untreated gastric ulcers - Active or previously documented autoimmune or inflammatory diseases requiring systemic treatment. - Brain metastases or central nervous system (CNS) diseases, including: epilepsy, seizures, aphasia, or stroke 3 months prior to consent, severe head injury, dementia, Parkinson's disease, neurodegenerative diseases, cerebellar diseases, severe uncontrolled psychiatric disorders, psychoses, autoimmune diseases involving the CNS. - History of other primary malignancies, except for malignancies such as basal cell carcinoma of the skin and squamous cell carcinoma of the skin, if for example for at least (≥ 2 years) (BASEC)
Luogo dello studio
Berna, Ginevra, Losanna, Zurigo
(BASEC)
Sponsor
Silviya Cantatore AstraZeneca Neuhofstrasse 34 6340 Baar silviya.cantatore@astrazeneca.com +41 41 725 75 75
(BASEC)
Contatto per ulteriori informazioni sullo studio
Persona di contatto in Svizzera
Clinical Trials Schweiz
+41 41 725 75 75
clinical-trials@clutterastrazeneca.comAstraZeneca AG Neuhofstrasse 34 6340 Baar
(BASEC)
Informazioni scientifiche
non disponibile
Nome del comitato etico approvante (per studi multicentrici solo il comitato principale)
Commissione etica Zurigo
(BASEC)
Data di approvazione del comitato etico
27.08.2024
(BASEC)
ID di studio ICTRP
non disponibile
Titolo ufficiale (approvato dal comitato etico)
CLARITY-Gastric01 - A Phase III Multi-center, Open-label, Sponsor-blinded, Randomized Study of AZD0901 Monotherapy Compared with Investigator’s Choice of Therapy in Second- or Later-Line Adult Participants with Advanced/Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2 (BASEC)
Titolo accademico
non disponibile
Titolo pubblico
non disponibile
Malattie studiate
non disponibile
Intervento studiato
non disponibile
Tipo di studio
non disponibile
Disegno dello studio
non disponibile
Criteri di inclusione/esclusione
non disponibile
non disponibile
Endpoint primari e secondari
non disponibile
non disponibile
Data di registrazione
non disponibile
Inclusione del primo partecipante
non disponibile
Sponsor secondari
non disponibile
Contatti aggiuntivi
non disponibile
ID secondari
non disponibile
Risultati-Dati individuali dei partecipanti
non disponibile
Ulteriori informazioni sullo studio
non disponibile
Risultati dello studio
Riepilogo dei risultati
non disponibile
Link ai risultati nel registro primario
non disponibile